A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer

Hoosier Cancer Research Network

Status and phase

Terminated

Phase 2

Conditions

Metastatic Breast Cancer

Treatments

Other: Imaging

Drug: Bevacizumab

Drug: Sorafenib

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00632541

BRE06-109

Details and patient eligibility

About

Prior clinical trials involving bevacizumab and sorafenib have demonstrated single agent activity in previously treated advanced breast cancer. This trial will test combined VEGF inhibition with sorafenib and bevacizumab in less heavily pre-treated patients with advanced breast cancer.

Full description

OUTLINE: This is a multi-center study.

Sorafenib 200mg po daily Bevacizumab 5mg/kg every other week

1 Cycle = 4 weeks Imaging every third cycle

Acceptable toxicity and non-PD = Protocol therapy will continue Un-acceptable toxicity or PD = Protocol therapy will be discontinued

ECOG Performance Status 0-1

Life Expectancy: at least 12 weeks

Hematopoietic:

Platelets > 100 K/mm3
Absolute neutrophil count (ANC) > 1.5 K/mm3
Hemoglobin > 10 g/dL

Hepatic:

Total Bilirubin < 1.5 x ULN
Aspartate aminotransferase (AST, SGOT) < 2 x ULN (up to 5 x ULN in patients with known liver involvement)

Renal:

Creatinine < 1.5 x ULN
No proteinuria as demonstrated by either Urine protein:creatinine (UPC) ratio < 1.0 or Urine dipstick for proteinuria < 2+

Cardiovascular:

No known myocardial infarction, unstable angina, > grade II New York Heart Association (NYHA) classification, congestive heart failure, uncontrolled hypertension defined as SBP >150 or DBP >100, > grade II peripheral vascular disease or significant vascular disease (e.g. aortic aneurysm, aortic dissection) within 12 months prior to being registered for protocol therapy.
No uncontrolled or clinically significant arrhythmia. NOTE: Controlled atrial fibrillation is allowed.
LVEF ≥ LLN by MUGA or ECHO as obtained within 28 days prior to being registered for protocol therapy.

Pulmonary:

No pulmonary hemorrhage/bleeding event ≥ CTCAE grade 2 within 28 days prior to being registered for protocol therapy.

Enrollment

18 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologic or cytologic diagnosis of breast cancer with evidence of metastatic disease. NOTE: Patients with Her-2 positive (3+ by IHC or gene amplification by FISH) are eligible only if they have had prior trastuzumab therapy.
Must have measurable or non-measurable lesions as defined by the Response Evaluation Criteria in Solid Tumors (RECIST).
Two or fewer prior chemotherapy regimens in any disease setting. NOTE: All adjuvant and neoadjuvant chemotherapy will be considered one regimen. NOTE: Prior hormonal therapy for metastatic disease is allowed. NOTE: Prior radiation therapy is allowed as long as the irradiated area is not the only source of evaluable disease.
Age > 18 years at the time of consent.
Written informed consent and HIPAA authorization for release of personal health information.
Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 8 weeks after treatment discontinuation.
Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy.
Ability to comply with study and/or follow-up procedures.

Exclusion criteria

No prior therapy with bevacizumab, sorafenib or any other known VEGF inhibitors.
No known hypersensitivity to any component of the study drugs.
No other forms of cancer therapy including radiation, chemotherapy and hormonal therapy within 21 days prior to being registered for protocol therapy.
No history or radiologic evidence of CNS metastases including previously treated, resected, or asymptomatic brain lesions or leptominigeal involvement. A head CT or MRI must be obtained within 28 days prior to being registered for protocol therapy.
No other participation in another clinical drug study within 28 days prior to being registered for protocol therapy.
No known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C
No major surgical procedure within 28 days prior to being registered for protocol therapy or anticipation of need for major surgical procedure during the course of the study. Placement of a vascular access device and breast biopsy will not be considered major surgery.
No minor surgical procedure within 7 days prior to being registered for protocol therapy.
No known history of cerebrovascular disease including TIA, stroke or subarachnoid hemorrhage.
No known history of ischemic bowel.
No known history of deep venous thrombosis or pulmonary embolism.
No history of hypertensive crisis or hypertensive encephalopathy.
No non-healing wound or fracture.
No active infection requiring parenteral antibiotics.
No other hemorrhage/bleeding event ≥ CTCAE grade 3 within 28 days prior to being registered for protocol therapy.